Crossmark

MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K/AKT/mTOR signaling pathway

Crossref DOI link: https://doi.org/10.1186/s13046-025-03482-9

Published Online: 2025-07-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guan, Rui

Li, Ce

Jiao, Ruijie

Li, Jingao

Wei, Ran

Feng, Chen

Cao, Shengda

Qian, Ye

Fang, Jugao

Liu, Jun

Li, Wenming

Wei, Dongmin

Lei, Dapeng
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82203770, 82471149)

Natural Science Foundation of Shandong Province (ZR2023MH153)
License Information

Text and Data Mining valid from 2025-07-26

Version of Record valid from 2025-07-26
More Information

Article History

Received: 20 April 2025

Accepted: 17 July 2025

First Online: 26 July 2025

Declarations

:

: This study was approved by the Ethics Committee of Qilu Hospital, Shandong University and signed informed consent was obtained from all patients. Animal experiments were performed according to the guidelines of the Animal Care and Use Committee of The First Clinical Medical School, Shandong University. This study was conducted in accordance with the Declaration of Helsinki.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below